Vimarsana
Biggest News Aggregation in the World

Page 12 - Project Orbis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Project Orbis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Project Orbis Today - Breaking & Trending Today

Report says 20% of global cancer deaths could be avoided - Vimarsana News

Report says 20% of global cancer deaths could be avoided

A new study by the Bloomberg New Economy International Cancer Coalition says at least 20% of global cancer deaths could be avoided each year.

Lack of global regulatory coordination for cancer clinical trials costs 1.5 million lives a year despite therapies being available - Vimarsana News

Lack of global regulatory coordination for cancer clinical trials costs 1.5 million lives a year despite therapies being available

/PRNewswire/ -- A new study by members of the Bloomberg New Economy International Cancer Coalition (the Coalition) says that at least 1.5 million deaths...

Cancer treatment: Are we stalling the cure? - Vimarsana News

Cancer treatment: Are we stalling the cure?

Around 1.5 million lives could be saved every year if the world worked together to more swiftly approve new cancer drugs.

FDA Approves Durvalumab Plus Chemo for Biliary Tract Cancer - Vimarsana News

FDA Approves Durvalumab Plus Chemo for Biliary Tract Cancer

The immune checkpoint inhibitor is already approved for use in lung cancer. Now it is also approved for use in combination with chemotherapy for locally advanced or metastatic biliary tract cancer.

IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Pa - Vimarsana News

IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Pa

Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy aloneWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tra...